Rapid Therapeutic Science Laboratories, Inc is focused on developing potential commercial opportunities which involve the rapid application of therapeutics using inhaler technology. The Company is also focusing on manufacturing its own branded metered dose inhaler (MDI) under the inhaler brand name.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume

Delayed Quote OTC Markets

More quotes

Market Closed - OTC Markets 09:40:58 21/08/2026 pm IST			5-day change	1st Jan Change
0.000400 ^USD	+300.00%		-.--%	-73.33%

15/23/15	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI
12/23/12	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI

Market Cap	85.73T 73.77T 69.46T 63.29T 1L 81.58L 1L 8L 3L 41.56L 3L 3L 1.32Cr	P/E 2021	-16.6x	P/E 2022	-3.24x
Enterprise Value	39.16L 33.7L 31.73L 28.91L 54.1L 37Cr 54.31L 3.76Cr 1.45Cr 19Cr 1.47Cr 1.44Cr 60Cr	EV / Sales 2021	93,97,88,53,933x	EV / Sales 2022	-
Free-Float	100%	Yield 2021 *	-	Yield 2022	-

15/23/15	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI
12/23/12	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI
31/23/31	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	CI
30/23/30	Rapid Therapeutic Science Laboratories, Inc. Auditor Raises 'Going Concern' Doubt	CI
11/22/11	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	CI
13/22/13	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	CI
31/22/31	Rapid Therapeutic Science Laboratories, Inc. announced that it has received $0.35 million in funding	CI
12/22/12	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	CI
17/22/17	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	CI
16/22/16	Rapid Therapeutic Science Laboratories, Inc. Auditor Raises 'Going Concern' Doubt	CI
28/22/28	Rapid Therapeutic Science Laboratories, Inc. announced that it has received $0.4 million in funding	CI
18/22/18	Rapid Therapeutic Science Laboratories, Inc. announced that it has received $0.15375 million in funding from Sixth Street Lending, LLC	CI
11/21/11	Rapid Therapeutics Science Laboratories Announces Launch of its New Facility Located in Addison, Tex	CI

07/23/07	Rapid Therapeutic Science Laboratories : Change in Certifying Accountants - Form 8-K	PU
31/23/31	RAPID THERAPEUTIC SCIENCE LABORATORIES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	AQ
21/23/21	White House Office of Management and Budget review on Cannabis-Derived Products confirms Rapid Therapeutic Science Laboratories’ Long-Term Strategy	AQ
13/22/13	Rapid Therapeutic Science Laboratories Updates Patents	AQ
11/22/11	RAPID THERAPEUTIC SCIENCE LABORATORIES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	AQ

Rapid Therapeutic Science Laboratories, Inc. Share Price

Stocks

RTSL

US7534312043

Pharmaceuticals

Valuation : Rapid Therapeutic Science Laboratories, Inc.

Chart: Rapid Therapeutic Science Laboratories, Inc.

Latest news : Rapid Therapeutic Science Laboratories, Inc.

Press Releases : Rapid Therapeutic Science Laboratories, Inc.

Quotes and Performance

Price Extremes

Managers and Directors : Rapid Therapeutic Science Laboratories, Inc.

Latest insider transactions

Alternative Medicine

Financials

Company Profile

Quotes

1 day	+300.00%
1 month	+300.00%
3 months	+300.00%
6 months	-93.33%
Current year	-73.33%

1 month	0		0
Current year	0		0.01
1 year	0		0.01
3 years	0		0.02
5 years	0		12.5
10 years	0		125

Manager	Title	Age	Since
Donal Schmidt CEO	Chief Executive Officer	65	15/11/2019
D. Watler DFI	Director of Finance/CFO	77	15/11/2019

Director	Title	Age	Since
D. Watler BRD	Director/Board Member	77	15/11/2019
Donal Schmidt BRD	Director/Board Member	65	15/11/2019

Date	Insider	Type	Main position	Quantity	% Market Cap.
27/12/21	Texas Mdi, Inc.	Don	Company	20,00,000	1.0332%
27/12/21	Sean Berrier	Don	Executive/Senior Manager	20,00,000	1.0332%
27/08/21	Henry Punzi	Other	Director	1,25,000	0.0646%

	2021	2022
Net sales	0 0 0 0 0 0.05 0 0.01 0 0.03 0 0 0.08	-
Net income	-28.68L -24.68L -23.24L -21.17L -39.61L -27Cr -39.77L -2.75Cr -1.06Cr -14Cr -1.08Cr -1.05Cr -44Cr	-17.95L -15.44L -14.54L -13.25L -24.79L -17Cr -24.89L -1.72Cr -66.61L -8.7Cr -67.39L -65.93L -28Cr
Net Debt	17.93L 15.43L 14.53L 13.24L 24.77L 17Cr 24.87L 1.72Cr 66.54L 8.69Cr 67.33L 65.86L 28Cr	38.31L 32.96L 31.04L 28.28L 52.91L 36Cr 53.12L 3.68Cr 1.42Cr 19Cr 1.44Cr 1.41Cr 59Cr

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
RAPID THERAPEUTIC SCIENCE LABORATORIES, INC.	+300.00%	-.--%	-87.50%	-92.00%	7.59T
YUNNAN BAIYAO GROUP CO.,LTD	-0.79%	-0.26%	-15.59%	-4.72%	1.34TCr
BEIJING TONGRENTANG CO., LTD	-1.48%	+0.63%	-32.19%	-56.13%	490.31Cr
DONG-E-E-JIAO CO., LTD.	-0.34%	-1.50%	-5.29%	-3.79%	444.25Cr
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-1.20%	-0.32%	-10.13%	-28.54%	390.89Cr
HUBEI JUMPCAN PHARMACEUTICAL CO., LTD.	-0.39%	+2.96%	-1.00%	+1.46%	353.81Cr
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	-1.09%	-1.76%	-24.07%	+5.61%	349.91Cr
TASLY PHARMACEUTICAL GROUP CO., LTD	-1.10%	-1.64%	-11.88%	+7.31%	320.37Cr
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	-0.40%	-0.34%	-22.70%	-14.42%	232.28Cr
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	-1.14%	-0.70%	-28.95%	-14.25%	168.79Cr
Average	+29.21%	-0.54%	-23.93%	-19.95%	409.26Cr
Weighted average by Cap.	-0.87%	-0.61%	-16.07%	-11.64%